- Home
- CKPT vs CYBN Comparison
CKPT vs CYBN Comparison
Compare CKPT & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- CYBN
- Stock Information
- Founded
- CKPT 2014
- CYBN 2019
- Country
- CKPT United States
- CYBN Canada
- Employees
- CKPT N/A
- CYBN 50
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- CYBN Pharmaceuticals and Biotechnology
- Sector
- CKPT Health Care
- CYBN Health Care
- Exchange
- CKPT Nasdaq
- CYBN Nasdaq
- Market Cap
- CKPT 172.4M
- CYBN 191.1M
- IPO Year
- CKPT 2017
- CYBN N/A
- Fundamental
- Price
- CKPT $3.13
- CYBN $9.09
- Analyst Decision
- CKPT Strong Buy
- CYBN Strong Buy
- Analyst Count
- CKPT 3
- CYBN 3
- Target Price
- CKPT $12.00
- CYBN $111.50
- AVG Volume (30 Days)
- CKPT 753.4K
- CYBN 350.4K
- Earning Date
- CKPT 03-21-2025
- CYBN 02-28-2025
- Dividend Yield
- CKPT N/A
- CYBN N/A
- EPS Growth
- CKPT N/A
- CYBN N/A
- EPS
- CKPT N/A
- CYBN N/A
- Revenue
- CKPT $47,000.00
- CYBN N/A
- Revenue This Year
- CKPT N/A
- CYBN N/A
- Revenue Next Year
- CKPT $300,658.78
- CYBN N/A
- P/E Ratio
- CKPT N/A
- CYBN N/A
- Revenue Growth
- CKPT N/A
- CYBN N/A
- 52 Week Low
- CKPT $1.38
- CYBN $6.50
- 52 Week High
- CKPT $4.50
- CYBN $19.84
- Technical
- Relative Strength Index (RSI)
- CKPT 46.36
- CYBN 41.61
- Support Level
- CKPT $3.10
- CYBN $9.08
- Resistance Level
- CKPT $3.43
- CYBN $10.59
- Average True Range (ATR)
- CKPT 0.26
- CYBN 0.67
- MACD
- CKPT 0.00
- CYBN -0.04
- Stochastic Oscillator
- CKPT 33.03
- CYBN 13.76
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.